Evaluation of the Restera™ Serene™ System in Adults With Obstructive Sleep Apnea
A Multi-center Proof-of-concept Study to Assess the Safety and Effectiveness of the Restera™ Serene™ System When Stimulating the Hypoglossal Nerve Alone or the Hypoglossal Nerve Plus the Ansa Cervicalis Nerve for the Treatment of Obstructive Sleep Apnoea in Adult Participants.
Restera, Inc.
20 participants
Dec 1, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this multi-center proof-of-concept safety and efficacy study is to collect chronic sleep-related data following percutaneous placement of electrode arrays near the hypoglossal nerve and the ansa cervicalis in adults with obstructive sleep apnea.
Eligibility
Inclusion Criteria3
- Body Mass Index (BMI) ≤ 32 kg/m2
- AHI between 15-65 events/hour
- Participants who have either not tolerated, have failed or refused positive airway pressure (PAP)
Exclusion Criteria4
- Pregnancy or breast-feeding
- Significant upper airway anatomic abnormalities
- Significant positionally-dependent OSA
- Participants taking medications that may alter body weight
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Neurostimulation via Restera Serene System
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07303452